about
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodelingASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells.Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.MSI2 is required for maintaining activated myelodysplastic syndrome stem cells.Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomasAid is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cellsResistant Fusarium keratitis progressing to endophthalmitis.A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease.High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis.Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells.Histiocytic neoplasms in the era of personalized genomic medicine.Loss of BAP1 function leads to EZH2-dependent transformation.Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester diseaseSonographic appearance of a dermoid cyst (mature cystic teratoma) of the spleen.The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort.Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.miR-99 regulates normal and malignant hematopoietic stem cell self-renewal.Rapidly progressive primary leptomeningeal atypical teratoid/rhabdoid tumor: a report of 2 cases.Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.Erratum: Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status".Molecular characterization of the histiocytoses: Neoplasia of dendritic cells and macrophages.Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease.Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice.The clinical spectrum of Erdheim-Chester disease: an observational cohort studyImpaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor geneSynthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene MutationsAn activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.Oncogenic TRK fusions are amenable to inhibition in hematologic malignanciesMolecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell HistiocytosisGenetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesisA Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1Efficacy of MEK inhibition in patients with histiocytic neoplasms
P50
Q30355347-FE01C5BB-F0A0-4C88-A361-9AF5EACC962CQ33753763-CD059A2D-CF87-4897-BF35-3BC808DEE248Q34506732-5C6C5CFF-389E-4B88-A8B0-D429D3EA78E2Q36553791-3087F1E9-AFD9-45E3-A0B4-00E777326784Q36611010-3E2E7884-C27C-432B-BF3E-C5037F447953Q36984373-4BCF4DD5-C5A5-4A9A-8F2F-C0987B74D963Q37380143-FC04B406-ABFB-438C-A77C-B3B5ACD6C978Q37731158-6F568FE7-D29A-428A-8161-728A8EFE59F0Q37945056-F0F081D1-C225-4FEF-9C6A-504EAAFE6F84Q38602233-DDCEED78-1F4D-48C7-936B-A179DC656546Q38692332-C88F3222-179F-4757-83CC-33EAE55C85A2Q38747542-F7F9CDA3-F270-4B67-A9B1-8D68B6B82E54Q38752592-0A75E326-297B-40FA-BB2A-C780987223FBQ38814135-2230E611-4D44-423F-9615-158CB0427294Q38830247-3E0BD326-B94E-4571-B87B-7DACEA85F990Q42386218-F056E11B-5771-4723-8EFA-FC281951A126Q43962982-238C4D46-60C4-4F66-81C8-976DEE30CCCDQ47563939-6D4E22C2-9E08-4133-AFE5-70CA060EE182Q48022696-63494CB0-032C-4305-8F21-F4DCA5AAFE60Q48364240-A447B8BE-20E3-4DFC-AA42-FD779AC9A341Q48634930-8F70A1C4-CEC3-4BE4-AC1A-92B0BED52B9BQ49568680-53D28F7A-894F-4C21-AAA3-B3435A1E8151Q51716289-B494849A-C281-4F2F-995B-0A8DCB43BDF4Q51716295-817BBCA8-43D9-4CEF-B042-83AB02DD0465Q52662040-F28574E6-7AE1-4AE2-B5BA-CF5A1D942ADEQ52689208-5AC21EE5-03A1-4441-BCAD-F19ACAF8E92FQ52714518-7D367AC1-1818-4569-B1B6-93D774E66FC8Q52724284-F090322C-5756-47C2-9AC3-DFB4784B72C5Q57453129-1F7EDDA3-BF24-4E29-B9D4-5856C5686AD9Q57465846-5D3CE19A-222E-4840-A4A6-3379FE2822F4Q63649314-D738ED85-2390-43C5-B1FC-41B415B06419Q64937209-5EBB2049-D2CC-4504-888D-29D68B497997Q89151574-B316C1F6-EFAA-4A85-B1F1-F7E54101B9BEQ90250949-E1661A8C-9D3D-499C-B7BF-457111A6075BQ90670701-4B8E9EEB-960D-4577-B17F-A3EAE3072BAFQ91862375-1411423D-903D-47D5-9744-1026C1F4FF3EQ92342062-FCF32720-1FF8-4E43-BFF6-530070300B85
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Benjamin Durham
@ast
Benjamin Durham
@en
Benjamin Durham
@es
Benjamin Durham
@nl
Benjamin Durham
@sl
type
label
Benjamin Durham
@ast
Benjamin Durham
@en
Benjamin Durham
@es
Benjamin Durham
@nl
Benjamin Durham
@sl
prefLabel
Benjamin Durham
@ast
Benjamin Durham
@en
Benjamin Durham
@es
Benjamin Durham
@nl
Benjamin Durham
@sl
P108
P106
P108
P1153
56481269400
P21
P31
P496
0000-0001-8090-5448